Checkpoint Inhibitor Refractory Cancer Market Segmentation:
By Mechanism of Action
- PD-1 Inhibitors
- PD-L1 Inhibitors
- CTLA-4 Inhibitors
- IDO1 Inhibitors
- A2AR Inhibitors
- LAG3 Inhibitors
- Others
By Cancer Type
- Lung Cancer
- Melanoma
- Renal Cell Carcinoma
- Bladder Cancer
- Head and Neck Cancer
- Hodgkin's Lymphoma
- Others
By Route of Administration
- Intravenous
- Oral
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel,
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
Frequently Asked Questions
The current market size of the checkpoint inhibitor refractory cancer market is estimated at USD 3.4 billion in 2023.
Increasing cancer prevalence globally, rising cases of resistance to checkpoint inhibitors, Strong R&D focus and pipeline products, Advances in combination therapies, Emergence of niche inhibitors and novel platforms, Growing diagnostic capabilities
Major players in Checkpoint Inhibitor Refractory Cancer Market: Merck, Amgen, AstraZeneca, Roche, Pfizer, Novartis, AbbVie, GlaxoSmithKline, Sanofi, Gilead Sciences, Takeda, Bristol-Myers Squibb, Merck KGaA, Regeneron, Moderna, Johnson & Johnson, Eli Lilly, Bayer, Daiichi Sankyo, Eisai
CAGR of 27.8% and market size of USD 19.1 billion by 2030